EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
Elizabeth C SmythGeorgios VlachogiannisSomaieh HedayatAlice HarberySanna Hulkki-WilsonMassimiliano SalatiKyriakos KouvelakisJavier Fernandez-MateosGeorge D CresswellElisa FontanaTherese SeidlitzClare PeckittJens C HahneAndrea LampisRuwaida BegumDavid WatkinsSheela RaoNaureen StarlingTom WaddellAlicia OkinesTom CrosbyWas MansoorJonathan WadsleyGary MiddletonMatteo FassanAndrew WotherspoonChiara BraconiIan ChauIgor VivancoAndrea SottorivaDaniel E StangeDavid CunninghamNicola ValeriPublished in: Gut (2020)
EGFR CN can be accurately measured in tissue and liquid biopsies and may be used for the selection of aGEA patients. EGFR inhibitors may antagonise the antitumour effect of anthracyclines with important implications for the design of future combinatorial trials.
Keyphrases
- label free
- phase iii
- small cell lung cancer
- open label
- clinical trial
- epidermal growth factor receptor
- tyrosine kinase
- end stage renal disease
- double blind
- phase ii
- placebo controlled
- study protocol
- ejection fraction
- newly diagnosed
- chronic kidney disease
- locally advanced
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- current status
- patient reported outcomes
- rectal cancer
- chemotherapy induced
- wild type
- nucleic acid